Invent Medic Sweden (IMS) Q4 2024 earnings summary

Executive summary

• Net sales for Q4 2024 reached 2,056 KSEK, up slightly from 2,015 KSEK in Q4 2023; full-year net sales grew to 7,345 KSEK from 6,707 KSEK year-over-year.

• Efemia Bladder Support sales and order intake continued to grow, with a 46% increase in product sales during 2024 and the strongest quarter to date.

• The company completed a rights issue and directed share issues post-period, strengthening key financial ratios and liquidity.

• CEO transition: Anna Lindström departed, succeeded by Gunilla Nilsson as of March 1, 2025, with Helena Liljedahl as interim CEO.

Financial highlights

• Q4 2024 result before tax was -2,458 KSEK (Q4 2023: -2,230 KSEK); full-year result before tax improved to -7,652 KSEK from -8,532 KSEK.

• EPS for Q4 was -0.04 SEK (-0.06); full-year EPS improved to -0.11 SEK (-0.21).

• Cash and cash equivalents at year-end were 1,248 KSEK (1,547 KSEK prior year).

• Operating expenses for the year decreased to -13,923 KSEK from -14,907 KSEK.

• Total cash flow for the year was -300 KSEK, an improvement from -1,506 KSEK in 2023.

Outlook and guidance

• The company aims to reach break-even in 2025, supported by recent capital injections.

• Positive indicators for continued growth in main markets, especially for Efemia Bladder Support.

• Strategic focus on expanding in Germany and strengthening partnerships with NGOs.